Medicine

The startup’s first disease target is chronic inflammatory demyelinating polyneuropathy (CIDP), which can be treated with a blockbuster Argenx drug. Nuvig aims to show its drug can offer a better way to treat this disease and other autoimmune conditions. The post Nuvig Therapeutics Nabs $161M to Build Case for a Better Approach to Autoimmune Disease…

Healthcare needs a better way to collect information from all sources, organize it, summarize it and present it to providers in a way that lets them deliver the necessary treatment, confident that the material is sound and verifiable. The post How the Right AI Can Improve Health Risk Assessments appeared first on MedCity News.

While many view Dr. Mehmet Oz’s nomination to lead the Centers for Medicare and Medicaid Services (CMS) with skepticism, there’s a compelling case that his unconventional background could catalyze long-overdue support for family caregivers. The post Dr. Oz at Medicare: Why America’s 53 Million Family Caregivers May Finally Get Their Due appeared first on MedCity…

Fello’s $10.4 million raise includes a seed investment from Glen Tullman’s 62Ventures, The Capital Factory Fellowship Fund, Katalyst Capital and Offline Ventures. The post Peer Support Platform Fello Secures $10.4M To Combat Loneliness Epidemic appeared first on MedCity News.

The Glp-1 battle heats with new preliminary data from Eli Lilly showing that patients using its weight loss drug Zepbound lost more weight on average in 72 weeks than those on Novo Nordisk’s Wegovy. The post Video: Battle of the Bulge – Wegovy vs. Zepbound appeared first on MedCity News.

It’s been a tumultuous past couple years for retail health companies —but there are still reasons to believe in the convenient model that retail health offers, said Annie Lamont, managing partner and co-founder of Oak HC/FT. The post Why One Investor Still Believes in Retail Health appeared first on MedCity News.

Eli Lilly obesity drug Zepbound led to 47% greater relative weight loss compared to Wegovy in a head-to-head clinical trial. The results could help Lilly differentiate its product from Novo Nordisk’s in the increasingly competitive market of obesity medications. The post Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head…

In response to emailed questions, the founders of MucoLife Therapeutics shared their company’s approach, which is designed to help people with COPD, cystic fibrosis, asthma, and pulmonary fibrosis. The post A Biotech Startup’s Quest to Relieve Pulmonary Mucus Obstruction for Respiratory Care appeared first on MedCity News.

Focusing on comprehensive strategies and embracing flexible technology solutions arms pharmacy leaders to stay ahead of industry changes, connect teams, and integrate information efficiently.  The post 10 Imperatives of a Medication Intelligence System to Streamline the Pharmacy Lifecycle appeared first on MedCity News.